NCT02726750 2026-04-16
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
M.D. Anderson Cancer Center
Recruiting
Clinical Trials
385 trialsNCT04839003 2026-04-16
ReAL
Fondazione IRCCS Policlinico San Matteo di Pavia
Recruiting
NCT05640843 2026-04-16
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
Memorial Sloan Kettering Cancer Center
Phase NA Recruiting
NCT06083922 2026-04-16
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06205953 2026-04-16
EUREKA
Fondazione IRCCS Policlinico San Matteo di Pavia
Recruiting
NCT06383143 2026-04-16
ProDigALIty
Fondazione IRCCS Policlinico San Matteo di Pavia
Recruiting
NCT06385652 2026-04-16
PET Imaging Study of 68Ga-NB381 in Multiple Myeloma
Peking University First Hospital
Phase EARLY_PHASE1 Recruiting
NCT06870760 2026-04-16
Pre-malignant States to Hematologic Malignancies in Firefighters
Wake Forest University Health Sciences
Recruiting
NCT03710421 2026-04-15
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
City of Hope Medical Center
Phase 1 Recruiting
NCT05136807 2026-04-15
Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
M.D. Anderson Cancer Center
Recruiting
NCT05336383 2026-04-15
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07382739 2026-04-14
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT01890486 2026-04-13
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
Wake Forest University Health Sciences
Recruiting
NCT03017820 2026-04-13
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Phase 1 Recruiting
NCT06145581 2026-04-13
Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma
Mayo Clinic
Phase NA Recruiting
NCT06483100 2026-04-13
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Washington University School of Medicine
Phase 2 Recruiting
NCT07032714 2026-04-13
MAGENTA
Massachusetts General Hospital
Phase 1 Recruiting
NCT05361694 2026-04-09
TRANSFORMM
University of Miami
Recruiting
NCT04300998 2026-04-07
Study of CAR-T Therapy in Older Patients
Memorial Sloan Kettering Cancer Center
Recruiting
NCT06048250 2026-04-07
Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
City of Hope Medical Center
Phase 1 Recruiting
NCT07514052 2026-04-07
Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study
Shanxi Bethune Hospital
Recruiting
NCT05969860 2026-04-03
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Mayo Clinic
Phase 2 Recruiting
NCT06252792 2026-04-03
Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma
The First Hospital of Jilin University
Recruiting
NCT06536413 2026-04-03
ATRA
The Methodist Hospital Research Institute
Phase 1/2 Recruiting
NCT07069751 2026-04-03
HiFi-MM
IRCCS San Raffaele
Phase NA Recruiting
NCT07509086 2026-04-03
IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
The First Hospital of Jilin University
Phase 2 Recruiting
NCT02693535 2026-04-02
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
NCT07290309 2026-03-31
SURGE
Colorado State University
Phase NA Recruiting
NCT05898646 2026-03-30
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
Mayo Clinic
Phase 2 Recruiting
NCT06270888 2026-03-30
Hypofractionation (Radiation) Trial for Multiple Myeloma
University of Chicago
Phase 1 Recruiting
NCT07045727 2026-03-30
Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase NA Recruiting
NCT05444920 2026-03-27
ITA-WebNet
Fondazione IRCCS Policlinico San Matteo di Pavia
Recruiting
NCT07181941 2026-03-27
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 1/2 Recruiting
NCT07497165 2026-03-27
Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
Shanxi Bethune Hospital
Recruiting
NCT06232044 2026-03-25
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
Alliance for Clinical Trials in Oncology
Phase 1/2 Recruiting
NCT07226934 2026-03-25
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
Washington University School of Medicine
Phase NA Recruiting
NCT07489534 2026-03-24
Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
Chinese PLA General Hospital
Phase 2 Recruiting
NCT01408225 2026-03-23
B-SCR-MM
Ohio State University Comprehensive Cancer Center
Recruiting
NCT07200102 2026-03-23
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
Washington University School of Medicine
Phase 1 Recruiting
NCT05405387 2026-03-20
IMPACT
University of Utah
Phase 2 Recruiting
NCT05092451 2026-03-18
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05272826 2026-03-18
BOREALIS
Canadian Myeloma Research Group
Phase 2 Recruiting
NCT06138275 2026-03-13
Elranatamab in R/R Multiple Myeloma
Massachusetts General Hospital
Phase 2 Recruiting
NCT06348108 2026-03-13
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
University of California, San Francisco
Phase 1 Recruiting
NCT01962636 2026-03-12
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Phase NA Recruiting
NCT06142396 2026-03-12
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
Augusta University
Phase EARLY_PHASE1 Recruiting
NCT06832865 2026-03-12
ELISA in Relapsed/Refractory MM
Massachusetts General Hospital
Phase 2 Recruiting
NCT05896228 2026-03-11
Iber-KDd
University of Miami
Phase 2 Recruiting
NCT06066359 2026-03-11
Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT06185751 2026-03-11
Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
Washington University School of Medicine
Phase 1 Recruiting